Identification

Name
Quinapril
Accession Number
DB00881  (APRD00523)
Type
Small Molecule
Groups
Approved, Investigational
Description

Quinapril is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to quinaprilat (quinapril diacid) following oral administration. Quinaprilat is a competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Quinapril may be used to treat essential hypertension and congestive heart failure.

Structure
Thumb
Synonyms
  • Quinaprilum
External IDs
C09AA06
Product Ingredients
IngredientUNIICASInChI Key
Quinapril Hydrochloride33067B3N2M82586-55-8IBBLRJGOOANPTQ-JKVLGAQCSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AccuprilTablet, film coated10 mg/1OralCardinal Health1991-11-192017-12-22Us
AccuprilTablet, film coated20 mg/1OralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
AccuprilTablet, film coated40 mg/1Oralbryant ranch prepack1991-11-192018-04-05Us
AccuprilTablet, film coated10 mg/1OralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
AccuprilTablet, film coated20 mg/1OralCardinal Health1991-11-192017-12-22Us
AccuprilTablet, film coated40 mg/1OralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
AccuprilTablet, film coated5 mg/1OralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
Accupril 5mg TabTablet5 mgOralPfizer1992-12-31Not applicableCanada
Accupril Tab 10mgTablet10 mgOralPfizer1992-12-31Not applicableCanada
Accupril Tab 20mgTablet20 mgOralPfizer1992-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-quinaprilTablet10 mgOralApotex Corporation2013-07-02Not applicableCanada
Apo-quinaprilTablet40 mgOralApotex Corporation2013-07-02Not applicableCanada
Apo-quinaprilTablet5 mgOralApotex Corporation2013-07-02Not applicableCanada
Apo-quinaprilTablet20 mgOralApotex Corporation2013-07-02Not applicableCanada
Gd-quinaprilTablet20 mgOralGenmed A Division Of Pfizer Canada Inc2014-06-02Not applicableCanada
Gd-quinaprilTablet10 mgOralGenmed A Division Of Pfizer Canada Inc2014-06-02Not applicableCanada
Gd-quinaprilTablet40 mgOralGenmed A Division Of Pfizer Canada Inc2014-06-02Not applicableCanada
Gd-quinaprilTablet5 mgOralGenmed A Division Of Pfizer Canada Inc2014-06-02Not applicableCanada
PMS-quinaprilTablet10 mgOralPharmascience Inc2013-11-18Not applicableCanada
PMS-quinaprilTablet40 mgOralPharmascience Inc2013-11-18Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AccureticQuinapril Hydrochloride (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralParke Davis Div Of Pfizer Inc1999-12-28Not applicableUs
AccureticQuinapril Hydrochloride (20 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralParke Davis Div Of Pfizer Inc1999-12-28Not applicableUs
AccureticQuinapril Hydrochloride (20 mg/1) + Hydrochlorothiazide (25 mg/1)Tablet, film coatedOralParke Davis Div Of Pfizer Inc1999-12-28Not applicableUs
Accuretic 10/12.5 mgQuinapril (10 mg) + Hydrochlorothiazide (12.5 mg)TabletOralPfizer1998-10-01Not applicableCanada
Accuretic 20/12.5 mgQuinapril (20 mg) + Hydrochlorothiazide (12.5 mg)TabletOralPfizer1998-10-01Not applicableCanada
Accuretic 20/25 mgQuinapril (20 mg) + Hydrochlorothiazide (25 mg)TabletOralPfizer2003-06-02Not applicableCanada
Apo-quinapril/hctzQuinapril (10 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2013-08-13Not applicableCanada
Apo-quinapril/hctzQuinapril (20 mg) + Hydrochlorothiazide (25 mg)TabletOralApotex Corporation2013-08-13Not applicableCanada
Apo-quinapril/hctzQuinapril (20 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2013-08-13Not applicableCanada
Gd-quinapril HctzQuinapril (10 mg) + Hydrochlorothiazide (12.5 mg)TabletOralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
International/Other Brands
Accuprin (Pfizer (Italy)) / Accupro (Pfizer (Austria, Denmark, Finland, Germany, Hungary, Ireland, Sweden, Switzerland, United Kingdom, Ukraine), Godecke (Czech Republic, Germany, Poland, Russia), Parke, Davis (Germany)) / Acequin / Acuitel / Korec / Quinazil
Categories
UNII
RJ84Y44811
CAS number
85441-61-8
Weight
Average: 438.5161
Monoisotopic: 438.21547208
Chemical Formula
C25H30N2O5
InChI Key
JSDRRTOADPPCHY-HSQYWUDLSA-N
InChI
InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1
IUPAC Name
(3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
SMILES
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O

Pharmacology

Indication

For the treatment of hypertension and as adjunct therapy in the treatment of congestive heart failure. May also be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.

Associated Conditions
Pharmacodynamics

Quinapril is a nonpeptide, non-sulfhydryl prodrug that is deesterified to quinaprilat (quinapril diacid), its major active metabolite following oral administration. Quinaprilat lowers blood pressure by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of quinaprilat by causing increased vasodilation and decreased blood pressure.

Mechanism of action

There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Quinaprilat, the principle active metabolite of quinapril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Quinaprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
Absorption

Peak plasma concentrations of quinapril occur within one hour following oral administration. The extent of absorption is at least 60%. The rate and extent of quinapril absorption are diminished moderately (approximately 25-30%) when ACCUPRIL tablets are administered during a high-fat meal.

Volume of distribution
Not Available
Protein binding

97%

Metabolism

Hepatic.

Route of elimination

Quinaprilat is eliminated primarily by renal excretion, up to 96% of an IV dose

Half life

Elimination half life is 2 hours with a prolonged terminal phase of 25 hours.

Clearance
Not Available
Toxicity

Overdose may lead to severe hypotension. LD50=1739mg/kg (orally in mice). The most common adverse effects observed in controlled clinical trials were dizziness, cough, chest pain, dyspnea, fatigue, and nausea/vomiting.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Quinapril Metabolism PathwayDrug metabolism
Quinapril Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Quinapril.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Quinapril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Quinapril.Approved, Investigational
AcebutololQuinapril may increase the hypotensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Quinapril.Approved, Investigational
AcemetacinThe therapeutic efficacy of Quinapril can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Quinapril can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Quinapril.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Quinapril.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Quinapril.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Quinapril.Approved, Investigational
AliskirenAliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Quinapril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Quinapril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Quinapril.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Quinapril.Approved
AloxiprinThe therapeutic efficacy of Quinapril can be decreased when used in combination with Aloxiprin.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Quinapril.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Quinapril.Approved, Withdrawn
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Quinapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmbrisentanQuinapril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Quinapril.Experimental, Investigational
AmifostineQuinapril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Quinapril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Quinapril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Quinapril.Approved
Aminosalicylic AcidThe therapeutic efficacy of Quinapril can be decreased when used in combination with Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Quinapril.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Quinapril.Approved
AmitriptylinoxideThe serum concentration of Amitriptylinoxide can be increased when it is combined with Quinapril.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Quinapril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Quinapril.Approved, Illicit
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Quinapril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Quinapril.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Quinapril.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Quinapril is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Quinapril.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Quinapril.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Quinapril.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Quinapril.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Quinapril.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Quinapril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Quinapril.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Quinapril.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Quinapril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Quinapril.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Quinapril.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Quinapril.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Quinapril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Quinapril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Quinapril.Withdrawn
AzathioprineThe risk or severity of anemia and severe leukopenia can be increased when Quinapril is combined with Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Quinapril.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Quinapril.Approved, Investigational
AzosemideAzosemide may increase the hypotensive activities of Quinapril.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Quinapril.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Quinapril.Experimental
BarbitalBarbital may increase the hypotensive activities of Quinapril.Illicit
BarnidipineQuinapril may increase the antihypertensive activities of Barnidipine.Approved
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Quinapril.Experimental
BendroflumethiazideThe risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Quinapril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Quinapril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Quinapril.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Quinapril.Withdrawn
BenzthiazideThe risk or severity of hypotension can be increased when Benzthiazide is combined with Quinapril.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Quinapril.Approved
BepridilQuinapril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Quinapril.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Quinapril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Quinapril.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Quinapril.Experimental
BimatoprostQuinapril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Quinapril.Approved
BoceprevirThe serum concentration of Quinapril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Quinapril.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Quinapril.Approved, Investigational
BQ-123Quinapril may increase the hypotensive activities of BQ-123.Investigational
BretyliumQuinapril may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Quinapril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Quinapril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Quinapril.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Quinapril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Quinapril.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Quinapril.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Quinapril.Experimental
BumetanideBumetanide may increase the hypotensive activities of Quinapril.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Quinapril.Approved, Investigational
BupranololQuinapril may increase the hypotensive activities of Bupranolol.Approved
ButriptylineThe serum concentration of Butriptyline can be increased when it is combined with Quinapril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Quinapril.Approved
CadralazineCadralazine may increase the hypotensive activities of Quinapril.Experimental
CafedrineQuinapril may increase the hypotensive activities of Cafedrine.Investigational
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Quinapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CanagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Quinapril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Quinapril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Quinapril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Quinapril.Experimental
CaptoprilQuinapril may increase the hypotensive activities of Captopril.Approved
Carbaspirin calciumThe therapeutic efficacy of Quinapril can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Quinapril.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Quinapril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Quinapril.Approved, Vet Approved, Withdrawn
CarvedilolQuinapril may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Quinapril.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Quinapril.Approved, Investigational
CeliprololQuinapril may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Quinapril.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hypotension can be increased when Chlorothiazide is combined with Quinapril.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Quinapril.Approved, Investigational, Vet Approved
ChlortetracyclineQuinapril can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of hypotension can be increased when Chlorthalidone is combined with Quinapril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Quinapril.Approved
CicletanineQuinapril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilQuinapril may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Quinapril.Approved, Investigational
CinoxacinQuinapril can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
CiprofloxacinQuinapril can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Quinapril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Quinapril is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Quinapril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Quinapril.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Quinapril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Quinapril.Approved
CloranololQuinapril may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Quinapril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Quinapril.Approved, Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Quinapril.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Quinapril.Approved, Investigational
CyclopenthiazideThe risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Quinapril.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Quinapril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe risk or severity of hyperkalemia can be increased when Quinapril is combined with Cyclosporine.Approved, Investigational, Vet Approved
DapagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Quinapril.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Quinapril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Quinapril.Approved, Investigational
DelaprilQuinapril may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Quinapril.Approved
DemeclocyclineQuinapril can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DersalazineThe therapeutic efficacy of Quinapril can be decreased when used in combination with Dersalazine.Investigational
DeserpidineQuinapril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Quinapril.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Quinapril.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Quinapril.Approved, Vet Approved
DexniguldipineQuinapril may increase the hypotensive activities of Dexniguldipine.Experimental
DiazoxideDiazoxide may increase the hypotensive activities of Quinapril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Quinapril.Experimental
DiclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diclofenac is combined with Quinapril.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Quinapril is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineQuinapril may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Quinapril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Quinapril.Experimental
DiflunisalThe therapeutic efficacy of Quinapril can be decreased when used in combination with Diflunisal.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Quinapril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Quinapril.Approved, Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Quinapril.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Quinapril.Approved, Investigational
DimetacrineThe serum concentration of Dimetacrine can be increased when it is combined with Quinapril.Approved, Withdrawn
DinutuximabThe risk or severity of adverse effects can be increased when Quinapril is combined with Dinutuximab.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Quinapril is combined with Dipyridamole.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Quinapril.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Quinapril.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Quinapril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Quinapril.Approved, Investigational
DoxycyclineQuinapril can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
DrospirenoneQuinapril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Quinapril.Withdrawn
DuloxetineQuinapril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Quinapril.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Quinapril.Approved
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Quinapril.Investigational
EfonidipineQuinapril may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Quinapril is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Quinapril.Approved, Vet Approved
EnalaprilatQuinapril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Quinapril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Quinapril.Approved, Investigational
EnoxacinQuinapril can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EpanololQuinapril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Quinapril.Approved
EpitizideThe risk or severity of hypotension can be increased when Epitizide is combined with Quinapril.Experimental
EplerenoneEplerenone may increase the hyperkalemic activities of Quinapril.Approved
EpoprostenolQuinapril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Quinapril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Quinapril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Quinapril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Quinapril.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Quinapril.Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Quinapril.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Quinapril.Approved, Investigational, Vet Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Quinapril.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Quinapril.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Quinapril.Experimental
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Quinapril.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Quinapril.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Quinapril.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Quinapril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Quinapril.Investigational, Nutraceutical
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Quinapril.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Quinapril.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Quinapril.Experimental
FelodipineQuinapril may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Quinapril.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Quinapril.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Quinapril.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Quinapril.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Quinapril.Experimental
Ferulic acidQuinapril may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Quinapril.Approved, Investigational
FleroxacinQuinapril can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Quinapril.Approved, Withdrawn
FlumequineQuinapril can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Quinapril.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Quinapril.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Quinapril.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Quinapril.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Quinapril.Approved
FostamatinibFostamatinib may increase the antihypertensive activities of Quinapril.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Quinapril.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Quinapril.Approved, Vet Approved
GarenoxacinQuinapril can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GarlicThe serum concentration of Quinapril can be decreased when it is combined with Garlic.Approved, Nutraceutical
GatifloxacinQuinapril can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GemifloxacinQuinapril can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GrepafloxacinQuinapril can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
GuacetisalThe therapeutic efficacy of Quinapril can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Quinapril.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Quinapril.Approved
GuanazodineQuinapril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineQuinapril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Quinapril.Approved, Investigational
GuanoclorQuinapril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzQuinapril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanQuinapril may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Quinapril.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Quinapril.Experimental
Hemoglobin crosfumarilThe therapeutic efficacy of Quinapril can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Quinapril is combined with Heparin.Approved, Investigational
HexamethoniumQuinapril may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Quinapril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Quinapril.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Quinapril.Experimental
HydralazineHydralazine may increase the hypotensive activities of Quinapril.Approved
HydrochlorothiazideThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Quinapril.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Quinapril.Approved, Investigational
IbuprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Quinapril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Quinapril.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Quinapril.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Quinapril.Approved, Investigational
ImidaprilQuinapril may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Quinapril.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Quinapril.Approved
IndapamideThe risk or severity of hypotension can be increased when Indapamide is combined with Quinapril.Approved
IndenololQuinapril may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Quinapril.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Quinapril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Quinapril.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Quinapril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Quinapril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Quinapril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Quinapril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Quinapril.Approved, Investigational
IronIron can cause a decrease in the absorption of Quinapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Quinapril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Quinapril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Quinapril.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Quinapril is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Quinapril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Quinapril.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Quinapril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Quinapril.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Quinapril.Experimental
KetanserinKetanserin may increase the hypotensive activities of Quinapril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Quinapril.Approved, Vet Approved
KetorolacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketorolac is combined with Quinapril.Approved
LabetalolLabetalol may increase the hypotensive activities of Quinapril.Approved
LacidipineQuinapril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Quinapril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Quinapril.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Quinapril.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Quinapril.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Quinapril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Quinapril.Approved, Investigational
LevodopaQuinapril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinQuinapril can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Quinapril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Quinapril.Approved
LinsidomineQuinapril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Quinapril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Quinapril.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Quinapril.Experimental
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Quinapril.Experimental
LofexidineQuinapril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomefloxacinQuinapril can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Quinapril.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Quinapril.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Quinapril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Quinapril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Quinapril.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Quinapril.Approved, Investigational
MacitentanQuinapril may increase the hypotensive activities of Macitentan.Approved
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Quinapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Quinapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Quinapril.Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Quinapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineQuinapril may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Quinapril.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Quinapril.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Quinapril.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Quinapril.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Quinapril.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Quinapril.Approved
MelitracenThe serum concentration of Melitracen can be increased when it is combined with Quinapril.Experimental, Investigational
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Quinapril.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Quinapril can be decreased when used in combination with Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Quinapril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Quinapril.Approved, Investigational, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Quinapril.Approved
MethohexitalMethohexital may increase the hypotensive activities of Quinapril.Approved
MethoserpidineQuinapril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of hypotension can be increased when Methyclothiazide is combined with Quinapril.Approved
Methyl salicylateThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Quinapril.Approved, Vet Approved
MethyldopaQuinapril may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Quinapril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Quinapril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Quinapril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Quinapril.Approved
MetipranololQuinapril may increase the hypotensive activities of Metipranolol.Approved
MetolazoneThe risk or severity of hypotension can be increased when Metolazone is combined with Quinapril.Approved
MetoprololMetoprolol may increase the hypotensive activities of Quinapril.Approved, Investigational
MetyrosineQuinapril may increase the hypotensive activities of Metyrosine.Approved
MibefradilQuinapril may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Quinapril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Quinapril.Approved
MinocyclineQuinapril can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MinoxidilMinoxidil may increase the hypotensive activities of Quinapril.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Quinapril.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Quinapril.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Quinapril.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Quinapril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Quinapril.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Quinapril.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Quinapril.Approved, Investigational
MoxifloxacinQuinapril can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Quinapril.Approved, Investigational
MuzolimineQuinapril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Quinapril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Quinapril.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Quinapril.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Quinapril.Approved
NadololQuinapril may increase the hypotensive activities of Nadolol.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Quinapril.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Quinapril.Approved
NaftopidilQuinapril may increase the hypotensive activities of Naftopidil.Investigational
Nalidixic AcidQuinapril can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NaproxenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Quinapril.Approved, Vet Approved
NebivololQuinapril may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Quinapril.Approved, Withdrawn
NemonoxacinQuinapril can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Quinapril.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Quinapril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Quinapril.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Quinapril.Approved, Investigational
NicorandilNicorandil may increase the vasodilatory activities of Quinapril.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Quinapril is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Quinapril.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Quinapril.Approved
NiguldipineQuinapril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineQuinapril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Quinapril.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Quinapril.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Quinapril.Approved
NitrendipineQuinapril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Quinapril.Approved
NitroaspirinThe therapeutic efficacy of Quinapril can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Quinapril.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Quinapril.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Quinapril.Approved, Investigational
NorfloxacinQuinapril can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Quinapril.Approved
ObinutuzumabQuinapril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Quinapril.Withdrawn
OfloxacinQuinapril can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Quinapril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Quinapril.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Quinapril.Approved
OmapatrilatQuinapril may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleOmeprazole can cause a decrease in the absorption of Quinapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Quinapril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Quinapril.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Quinapril.Approved
Oxolinic acidQuinapril can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
OxprenololQuinapril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Quinapril.Approved, Withdrawn
OxytetracyclineQuinapril can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Quinapril.Approved, Vet Approved
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Quinapril.Experimental, Nutraceutical
PapaverineThe risk or severity of adverse effects can be increased when Quinapril is combined with Papaverine.Approved, Investigational
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Quinapril.Approved
PargylinePargyline may increase the hypotensive activities of Quinapril.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Quinapril.Approved, Investigational
Patent BlueThe therapeutic efficacy of Quinapril can be decreased when used in combination with Patent Blue.Approved
PazufloxacinQuinapril can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinQuinapril can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenbutololQuinapril may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Quinapril.Approved, Investigational, Vet Approved
PentoliniumQuinapril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Quinapril.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Quinapril.Approved
PethidineThe risk or severity of adverse effects can be increased when Quinapril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Quinapril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Quinapril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Quinapril.Approved, Investigational
PhenoxybenzamineQuinapril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Quinapril.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Quinapril.Approved
Phenyl aminosalicylateThe therapeutic efficacy of Quinapril can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Quinapril.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Quinapril.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Quinapril.Approved
PindololQuinapril may increase the hypotensive activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Quinapril.Approved, Investigational
Pipemidic acidQuinapril can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PiretanidePiretanide may increase the hypotensive activities of Quinapril.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Quinapril.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Quinapril.Approved
Piromidic acidQuinapril can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Quinapril.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Quinapril.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Quinapril.Withdrawn
Platelet Activating FactorQuinapril may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideThe risk or severity of hypotension can be increased when Polythiazide is combined with Quinapril.Approved
Potassium bicarbonatePotassium bicarbonate may increase the hyperkalemic activities of Quinapril.Approved
Potassium cationPotassium may increase the hyperkalemic activities of Quinapril.Approved, Investigational
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Quinapril.Approved, Withdrawn
Potassium CitratePotassium Citrate may increase the hyperkalemic activities of Quinapril.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Quinapril.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Quinapril.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Quinapril.Approved
PregabalinThe risk or severity of angioedema can be increased when Quinapril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Quinapril.Approved, Vet Approved
ProcaineProcaine may increase the hypotensive activities of Quinapril.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Quinapril.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Quinapril.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Quinapril.Approved, Investigational
PropafenoneThe risk or severity of hyperkalemia can be increased when Quinapril is combined with Propafenone.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Quinapril.Approved, Investigational, Vet Approved
PropranololQuinapril may increase the hypotensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Quinapril.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Quinapril.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Quinapril.Approved
PrulifloxacinQuinapril can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Quinapril.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quinapril is combined with Quetiapine.Approved
QuinethazoneThe risk or severity of hypotension can be increased when Quinethazone is combined with Quinapril.Approved
QuinineQuinine may increase the hypotensive activities of Quinapril.Approved
RamiprilRamipril may increase the hypotensive activities of Quinapril.Approved
RasagilineRasagiline may increase the hypotensive activities of Quinapril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quinapril.Approved
RemikirenRemikiren may increase the hypotensive activities of Quinapril.Approved
RescinnamineQuinapril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Quinapril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Quinapril.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Quinapril.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Quinapril.Approved
RisperidoneQuinapril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabQuinapril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Quinapril.Approved, Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Quinapril.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Quinapril.Approved
RosoxacinQuinapril can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Quinapril.Approved
RufloxacinQuinapril can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SacubitrilThe risk or severity of angioedema can be increased when Quinapril is combined with Sacubitril.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Quinapril.Approved
Salicylic acidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylic acid is combined with Quinapril.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Quinapril.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Quinapril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Quinapril.Investigational
SaxagliptinThe risk or severity of angioedema can be increased when Saxagliptin is combined with Quinapril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Quinapril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Quinapril.Approved, Investigational, Vet Approved
SelexipagQuinapril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Quinapril.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Quinapril.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Quinapril.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Quinapril.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Quinapril.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Quinapril.Approved
SirolimusThe risk or severity of angioedema can be increased when Sirolimus is combined with Quinapril.Approved, Investigational
SitafloxacinQuinapril can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
SitagliptinThe risk or severity of angioedema can be increased when Sitagliptin is combined with Quinapril.Approved, Investigational
SitaxentanQuinapril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Quinapril is combined with Sodium aurothiomalate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of nephrotoxicity can be increased when Quinapril is combined with Sodium phosphate, monobasic.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Quinapril.Approved
SparfloxacinQuinapril can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
SpiraprilQuinapril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of hyperkalemia can be increased when Spironolactone is combined with Quinapril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Quinapril.Investigational
St. John's WortThe metabolism of Quinapril can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Quinapril.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quinapril.Approved, Investigational
SulfasalazineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Quinapril.Approved
SulindacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Quinapril.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Quinapril.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Quinapril.Experimental
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Quinapril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Quinapril.Approved, Investigational
TalinololQuinapril may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Quinapril.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Quinapril.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Quinapril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Quinapril.Approved, Investigational
TemafloxacinQuinapril can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TemocaprilQuinapril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Quinapril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Quinapril.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Quinapril.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Quinapril.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Quinapril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Quinapril.Approved
TerlipressinQuinapril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetracyclineQuinapril can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TetrahydropalmatineQuinapril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Quinapril.Approved, Investigational, Withdrawn
TheodrenalineQuinapril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Quinapril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Quinapril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Quinapril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Quinapril.Approved, Withdrawn
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Quinapril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Quinapril.Approved
TiboloneQuinapril may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenQuinapril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Quinapril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Quinapril.Investigational
TipranavirThe serum concentration of Quinapril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of hypotension can be increased when Tizanidine is combined with Quinapril.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Quinapril.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Quinapril.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Quinapril.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Quinapril.Approved
TolonidineQuinapril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Quinapril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Quinapril.Approved
TorasemideTorasemide may increase the hypotensive activities of Quinapril.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Quinapril.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Quinapril.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Quinapril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Quinapril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Quinapril.Approved, Investigational, Nutraceutical
TriamtereneTriamterene may increase the hyperkalemic activities of Quinapril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Quinapril.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Quinapril.Experimental
TrichlormethiazideThe risk or severity of hypotension can be increased when Trichlormethiazide is combined with Quinapril.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Quinapril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Quinapril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Quinapril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Quinapril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Quinapril.Investigational
Trolamine salicylateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Quinapril.Approved
TrovafloxacinQuinapril can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
UdenafilUdenafil may increase the antihypertensive activities of Quinapril.Approved, Investigational
UnoprostoneQuinapril may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Quinapril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Quinapril.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Quinapril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Quinapril.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Quinapril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Quinapril.Approved, Investigational
VincamineQuinapril may increase the hypotensive activities of Vincamine.Experimental
XipamideQuinapril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineQuinapril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Quinapril.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Quinapril.Approved, Investigational
ZidovudineThe excretion of Quinapril can be decreased when combined with Zidovudine.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Quinapril.Approved, Investigational, Withdrawn
ZofenoprilQuinapril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Quinapril.Withdrawn
Food Interactions
  • Do not take with a high-fat meal.
  • Herbs that may attenuate the antihypertensive effect of quinapril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of quinapril.
  • Quinapril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.

References

Synthesis Reference

Om P. Goel, Uldis Krolls, "Crystalline quinapril and a process for producing the same." U.S. Patent US4761479, issued August, 1982.

US4761479
General References
  1. Khan BV, Sola S, Lauten WB, Natarajan R, Hooper WC, Menon RG, Lerakis S, Helmy T: Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care. 2004 Jul;27(7):1712-5. [PubMed:15220251]
  2. Kieback AG, Felix SB, Reffelmann T: Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1337-47. doi: 10.1517/17425250903282773. [PubMed:19761414]
  3. Pitt B, O'Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, Bass T, Pepine C, Texter M, Haber H, Uprichard A, Cashin-Hemphill L, Lees RS: The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001 May 1;87(9):1058-63. [PubMed:11348602]
  4. Tsikouris JP, Suarez JA, Meyerrose GE, Ziska M, Fike D, Smith J: Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction? J Clin Pharmacol. 2004 Feb;44(2):150-7. [PubMed:14747423]
  5. Valles Prats M, Matas Serra M, Bronsoms Artero J, Mate Benito G, Torguet Escuder P, Mauri Nicolas JM: Quinapril ACE-inhibition effects on adrenergic parameters in moderate essential hypertension. Kidney Int Suppl. 1996 Jun;55:S104-6. [PubMed:8743525]
  6. Voors AA, van Geel PP, Oosterga M, Buikema H, van Veldhuisen DJ, van Gilst WH: Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism. J Renin Angiotensin Aldosterone Syst. 2004 Sep;5(3):130-4. [PubMed:15526248]
  7. Yamada S, Muraoka I, Kato K, Hiromi Y, Takasu R, Seno H, Kawahara H, Nabeshima T: Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. Biol Pharm Bull. 2003 Jun;26(6):872-5. [PubMed:12808303]
External Links
Human Metabolome Database
HMDB0015019
KEGG Drug
D03752
KEGG Compound
C07398
PubChem Compound
54892
PubChem Substance
46506309
ChemSpider
49565
BindingDB
50368166
ChEBI
8713
ChEMBL
CHEMBL1592
Therapeutic Targets Database
DAP000588
PharmGKB
PA451205
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Quinapril
ATC Codes
C09AA06 — QuinaprilC09BA06 — Quinapril and diuretics
AHFS Codes
  • 24:32.04 — Angiotensin-converting Enzyme Inhibitors

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers4
3CompletedPreventionDiabetes, Diabetes Mellitus Type 11
4CompletedNot AvailableCABGs1
4CompletedNot AvailableDiabetic Autonomic Neuropathy1
4CompletedPreventionHigh Blood Pressure (Hypertension)1
4CompletedPreventionNonvalvular Atrial Fibrillation1
4CompletedTreatmentHigh Blood Pressure (Hypertension)2
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Menopause1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Induction of intra-operative hypotension1
4CompletedTreatmentIschaemic Heart Diseases1
4RecruitingTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes1
4TerminatedTreatmentHigh Blood Pressure (Hypertension)1
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension)1
Not AvailableCompletedTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1

Pharmacoeconomics

Manufacturers
  • Pfizer pharmaceuticals ltd
  • Actavis totowa llc
  • Apotex inc
  • Genpharm inc
  • Invagen pharmaceuticals inc
  • Lupin ltd
  • Mylan pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc florida
Packagers
  • Actavis Group
  • Apotex Inc.
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Aurobindo Pharma Ltd.
  • Cardinal Health
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Doctor Reddys Laboratories Ltd.
  • Eon Labs
  • Goedecke GmbH
  • Greenstone LLC
  • Heartland Repack Services LLC
  • InvaGen Pharmaceuticals Inc.
  • Lupin Pharmaceuticals Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Ohm Laboratories Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmacia Inc.
  • Physicians Total Care Inc.
  • Prepackage Specialists
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Resource Optimization and Innovation LLC
  • Southwood Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Dosage forms
FormRouteStrength
TabletOral5 mg
TabletOral10 mg
TabletOral20 mg
TabletOral40 mg
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral5 mg/1
TabletOral5 1/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral5 mg/1
TabletOral
Tablet, film coatedOral
Prices
Unit descriptionCostUnit
Accupril 10 mg tablet2.02USD tablet
Accupril 20 mg tablet2.02USD tablet
Accupril 40 mg tablet2.02USD tablet
Accupril 5 mg tablet2.02USD tablet
Quinapril 10 mg tablet1.57USD tablet
Quinapril 20 mg tablet1.57USD tablet
Quinapril 40 mg tablet1.57USD tablet
Quinapril 5 mg tablet1.57USD tablet
Quinapril HCl 10 mg tablet1.27USD tablet
Quinapril HCl 20 mg tablet1.27USD tablet
Quinapril HCl 40 mg tablet1.27USD tablet
Quinapril HCl 5 mg tablet1.27USD tablet
Quinaretic 10-12.5 mg tablet1.27USD tablet
Quinaretic 20-12.5 mg tablet1.27USD tablet
Quinaretic 20-25 mg tablet1.27USD tablet
Accupril 10 mg Tablet0.96USD tablet
Accupril 20 mg Tablet0.96USD tablet
Accupril 40 mg Tablet0.96USD tablet
Accupril 5 mg Tablet0.96USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5684016No1995-05-042015-05-04Us
CA2023089No2003-01-142010-08-10Canada
CA1331615No1994-08-232011-08-23Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)120-130 °CNot Available
water solubility1 mg/LNot Available
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0085 mg/mLALOGPS
logP1.39ALOGPS
logP1.96ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)3.7ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity119.96 m3·mol-1ChemAxon
Polarizability47.36 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5597
Blood Brain Barrier-0.9409
Caco-2 permeable-0.8208
P-glycoprotein substrateSubstrate0.8895
P-glycoprotein inhibitor IInhibitor0.7344
P-glycoprotein inhibitor IIInhibitor0.5869
Renal organic cation transporterNon-inhibitor0.8258
CYP450 2C9 substrateNon-substrate0.8594
CYP450 2D6 substrateNon-substrate0.8412
CYP450 3A4 substrateSubstrate0.5356
CYP450 1A2 substrateNon-inhibitor0.8597
CYP450 2C9 inhibitorNon-inhibitor0.6832
CYP450 2D6 inhibitorNon-inhibitor0.8636
CYP450 2C19 inhibitorNon-inhibitor0.6016
CYP450 3A4 inhibitorInhibitor0.5347
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5162
Ames testNon AMES toxic0.9091
CarcinogenicityNon-carcinogens0.9294
BiodegradationNot ready biodegradable0.9596
Rat acute toxicity2.2690 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9763
hERG inhibition (predictor II)Inhibitor0.7176
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Alpha amino acid esters / N-acyl-L-alpha-amino acids / Alpha amino acid amides / Tetrahydroisoquinolines / Fatty acid esters / Aralkylamines / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Tertiary carboxylic acid amides / Amino acids
show 8 more
Substituents
Alpha-dipeptide / Alpha-amino acid ester / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid or derivatives / Tetrahydroisoquinoline / Fatty acid ester / Aralkylamine / Monocyclic benzene moiety / Dicarboxylic acid or derivatives
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
dicarboxylic acid monoester, ethyl ester, isoquinolines (CHEBI:8713)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Culy CR, Jarvis B: Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs. 2002;62(2):339-85. [PubMed:11817979]
  3. Klutchko S, Blankley CJ, Fleming RW, Hinkley JM, Werner AE, Nordin I, Holmes A, Hoefle ML, Cohen DM, Essenburg AD, et al.: Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types. J Med Chem. 1986 Oct;29(10):1953-61. [PubMed:3020249]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Curator comments
Quinaprilat is the active metabolite of quinapril; its substrate profile was demonstrated in vitro using HEK293 cells.
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. VanWert AL, Gionfriddo MR, Sweet DH: Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos. 2010 Jan;31(1):1-71. doi: 10.1002/bdd.693. [PubMed:19953504]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:46